Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Pediatrix Medical Group Q1 2026 Earnings Call - Strong Pricing Outpaces Volume Declines, Full-Year Outlook Reaffirmed
Pediatrix Medical Group delivered a robust first quarter, driven by pricing strength that more than offset modest volume declines across service lines. Adjusted EBITDA came in at $58 million, supporte...
- Adjusted EBITDA reached $58 million in Q1 2026, exceeding expectations and reflecting strong top-line growth despite modest volume declines.
- Pricing growth of 4% outpaced same-unit volume growth of just under 3%, driven by robust revenue cycle management collections, favorable payer mix, increased neonatal acuity, and higher contract administrative fees.
- Full-year 2026 adjusted EBITDA guidance of $280 million to $300 million was reaffirmed, with management expressing confidence in the outlook despite potential macroeconomic headwinds.
- +7 more takeaways
"Surgery Partners" Q1 2026 Earnings Call - Margin Headwinds Offset by Strong Robotics and Physician Growth
Surgery Partners delivered a steady start to 2026, posting $811 million in net revenue and $102 million in adjusted EBITDA that tracked closely with internal expectations. While same-facility case gro...
- First quarter net revenue reached approximately $811 million, while adjusted EBITDA came in at $102 million, landing in line with internal expectations.
- Same-facility revenue growth accelerated to 4.4%, outpacing the modest 0.6% same-facility case growth, highlighting a successful shift toward higher-acuity procedures.
- Weather-related disruptions in January and February temporarily deflected lower-acuity cases, particularly in GI and ophthalmology, impacting case growth by roughly 40 basis points.
- +9 more takeaways
LCI Industries Q1 2026 Earnings Call - Margin Expansion Driven by Self-Help and Diversification Despite Weak RV Retail
LCI Industries delivered a resilient Q1 2026, growing revenue 4% to $1.1 billion while expanding adjusted EBITDA margins by 90 basis points to 11.5%. The results highlight the power of a decade-long d...
- Revenue grew 4% year-over-year to $1.1 billion, defying a sluggish retail and wholesale leisure market backdrop.
- Adjusted EBITDA margin expanded 90 basis points to 11.5%, with operating margin improving to 8.7% from 7.8% a year ago.
- RV OEM net sales declined 4%, but adjacent industry OEM sales surged 17%, driven by marine, bus, and utility trailer demand.
- +7 more takeaways
Ball Corporation Q1 2026 Earnings Call - EPS Surges 22% on Record Operating Leverage and EMEA Expansion
Ball Corporation delivered a forceful start to 2026, with comparable diluted EPS jumping 22% year-over-year and operating earnings climbing 10%. The results were driven by disciplined cost execution, ...
- Comparable diluted EPS surged 22% to $0.94, driven by 10% growth in operating earnings and disciplined cost management.
- Global shipped beverage volumes increased nearly 1% year-over-year, with low-single-digit growth in North America and EMEA offsetting mid-single-digit declines in South America due to customer inventory timing.
- EMEA segment comparable operating earnings jumped 20%, supported by the Benepack acquisition and strong operational performance, with volumes growing above the top end of the long-term 3%-5% range.
- +7 more takeaways
AH Realty Trust Q1 2026 Earnings Call - Multifamily Exit and Share Buybacks Signal Transformation
AH Realty Trust delivered a solid first quarter in 2026, with FFO as adjusted of $0.15 per share, exceeding internal expectations and driving an upgrade in full-year guidance to $0.51-$0.55. The compa...
- AH Realty Trust reported Q1 2026 FFO as adjusted of $0.15 per diluted share, beating internal expectations and prompting a raise in full-year guidance to $0.51-$0.55.
- The company entered a binding agreement to sell 11 multifamily assets for $562 million, a major step in exiting the residential sector to simplify its portfolio and reduce complexity.
- Proceeds from asset sales, totaling approximately $750 million from completed and pending transactions, will be used to de-lever the balance sheet to a target net debt to adjusted EBITDA of 5.5x to 6.5x.
- +7 more takeaways
Ocugen Q1 2026 Earnings Call - Gene Therapy Platform Advances with $115M Debt Financing and 2028 BLA Targets
Ocugen’s Q1 2026 results underscore a high-stakes pivot from clinical execution to commercial preparation across its gene therapy platform. The company closed enrollment in two late-stage trials, deli...
- Ocugen announced a $115 million offering of convertible senior notes, extending cash runway into 2028, with potential additional $15 million from warrant exercises.
- The company is advancing a gene-agnostic platform targeting master regulators in retinal diseases, aiming to treat 3 million patients across three late-stage programs.
- Phase III enrollment for OCU400 (retinitis pigmentosa) is complete, with rolling BLA submission expected in Q3 2026 and top-line data in Q1 2027.
- +7 more takeaways
ADM Q1 2026 Earnings Call - RVO Clarity and Ethanol Margins Drive Raised Guidance
ADM delivered a strong first quarter of 2026, driven by a constructive margin environment in ethanol and crushing following the EPA's finalization of Renewable Volume Obligations. The company raised i...
- ADM raised its full-year 2026 adjusted EPS guidance to $4.15-$4.70, up from $3.60-$4.25, citing constructive margin environments and strong execution.
- Q1 2026 adjusted EPS was $0.71, with total segment operating profit of $764 million and a trailing 4-quarter adjusted ROIC of 6.4%.
- The EPA's finalization of 2026 and 2027 Renewable Volume Obligations (RVOs) provided policy clarity, strengthening ethanol margins and soybean crush activity.
- +9 more takeaways
Marriott Vacations Worldwide Q1 2026 Earnings Call - Contract Sales Acceleration Signals Turnaround Inflection Point
Marriott Vacations Worldwide delivered a transitional first quarter, with contract sales down 2% and adjusted EBITDA declining 16% as the company executed on leadership changes, workforce reductions, ...
- Contract sales declined 2% year-over-year to $411 million, with VPG up 1% and tours down 3%, primarily due to planned Asia reductions and lower first-time buyer volume.
- Adjusted EBITDA fell 16% to $161 million, with margin compressing 370 basis points to 19%, reflecting higher marketing costs and product expenses amid transition.
- April contract sales surged 8% year-over-year, powered by an 11% North America lift, signaling that new sales talent and operational changes are gaining traction.
- +7 more takeaways
Integra LifeSciences Q1 2026 Earnings Call - CEO Returns, Guidance Raised, and Commercial Reset
Integra LifeSciences delivered a strong first quarter with revenue of $392 million and adjusted EPS of $0.54, beating the high end of guidance. The company maintained its full-year revenue outlook at ...
- CEO Stuart Essig returns to lead the company, stepping back into the role previously held by Mojdeh Poul, with a focus on commercial execution and culture.
- Full-year adjusted EPS guidance raised to $2.40-$2.50 from prior expectations, driven by tariff benefits and margin improvement.
- Q1 revenue of $392 million beat guidance, with organic growth of 1.3% and strong performance in Tissue Reconstruction.
- +7 more takeaways
UL Solutions Q1 2026 Earnings Call - Margin Expansion and Strategic M&A Drive Outperformance
UL Solutions delivered a standout first quarter in 2026, posting consolidated revenue growth of 7.5% and adjusted EBITDA margin expansion of 320 basis points to 26.0%. The results were driven by disci...
- Consolidated revenue grew 7.5% year-over-year to $758 million, with organic revenue growth of 5.7%, outpacing expectations.
- Adjusted EBITDA surged 22.4% to $197 million, driving a 320 basis point expansion in adjusted EBITDA margin to 26.0%.
- Management raised full-year 2026 adjusted EBITDA margin guidance to approximately 27.0%, up from the previous range, citing strong Q1 performance and restructuring savings.
- +7 more takeaways